1. Search Result
Search Result
Results for "

β3

" in MedChemExpress (MCE) Product Catalog:

441

阻害剤およびアゴニスト

5

蛍光色素

14

生化学アッセイ試薬

52

ペプチド

3

阻害性抗体

39

天然物

29

組換えタンパク質

34

同位体標識化合物

25

抗体

1

クリックケミストリー

7

オリゴヌクレオチド

製品番号 製品名 Target 研究分野 構造式
  • HY-P0023
    Cyclo(-RGDfK)
    Maximum Cited Publications
    27 Publications Verification

    Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    Cyclo(-RGDfK)
  • HY-14773
    Mirabegron
    5 Publications Verification

    YM178

    Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Mirabegron is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM.
    Mirabegron
  • HY-100563A
    Cyclo(RGDyK)
    4 Publications Verification

    Integrin Cancer
    Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
    Cyclo(RGDyK)
  • HY-100672
    SR59230A
    10+ Cited Publications

    Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively .
    SR59230A
  • HY-P0023A
    Cyclo(-RGDfK) TFA
    Maximum Cited Publications
    27 Publications Verification

    Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface [3].
    Cyclo(-RGDfK) TFA
  • HY-16143
    Cilengitide TFA
    Maximum Cited Publications
    70 Publications Verification

    EMD 121974 TFA

    Integrin Autophagy Cancer
    Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively.
    Cilengitide TFA
  • HY-19334
    L755507
    2 Publications Verification

    Adrenergic Receptor Endocrinology Cancer
    L755507 is a potent, selective agonist of β3-AR with an IC50 of 35 nM. L755507 enhances the homology-directed repair (HDR)-mediated genome editing [3].
    L755507
  • HY-19933
    Vibegron
    1 Publications Verification

    MK-4618

    Adrenergic Receptor Others
    Vibegron (MK-4618) is a potent, highly selective and orally active β3-adrenoceptor agonist (EC50=1.1 nM). Vibegron can be used for severe urgency urinary incontinence related to overactive bladder [3].
    Vibegron
  • HY-103200
    SR59230A hydrochloride
    10+ Cited Publications

    Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively .
    SR59230A hydrochloride
  • HY-172464

    Liposome Integrin Cancer
    DSPE-PEG2000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG2000-cRGD can be used for drug delivery .
    DSPE-PEG2000-cRGD
  • HY-103207

    SR 58611A

    Adrenergic Receptor Neurological Disease Endocrinology
    Amibegron hydrochloride is a selective β3-adrenoceptor agonist, with an EC50 of 3.5 nM for β-adrenoceptor in rat colon; Amibegron hydrochloride has anxiolytic and antidepressant activity.
    Amibegron hydrochloride
  • HY-103524
    Valerenic acid
    1 Publications Verification

    (-)-Valerenic Acid

    GABA Receptor 5-HT Receptor Neurological Disease
    Valerenic acid ((-)-Valerenic Acid), a sesquiterpenoid, is an orally active positive allosteric modulator of GABAA receptors. Valerenic acid is also a partial agonist of the 5-HT5a receptor. Valerenic acid mediates anxiolytic activity via GABAA receptors containing the β3 subunit. Valerenic acid also exhibits potent antioxidant properties [3].
    Valerenic acid
  • HY-100563
    Cyclo(RGDyK) trifluoroacetate
    4 Publications Verification

    Integrin Cancer
    Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
    Cyclo(RGDyK) trifluoroacetate
  • HY-P5133
    Synstatin (92-119)
    1 Publications Verification

    SSTN92-119

    Integrin Cancer
    Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .
    Synstatin (92-119)
  • HY-19436
    Solabegron
    1 Publications Verification

    GW 427353

    Adrenergic Receptor Metabolic Disease Endocrinology
    Solabegron (GW 427353) is a selective β3-adrenergic receptor agonist, stimulating cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 nM . Solabegron (GW 427353) is being developed for the treatment of overactive bladder and irritable bowel syndrome .
    Solabegron
  • HY-148804

    APD418

    Adrenergic Receptor Cardiovascular Disease
    Vemtoberant is a β3-adrenergic receptor inhibitor with a human Ki of 8.2 nM, and exhibits 400- to 600-fold selectivity over human β1-AR and β2-AR. Vemtoberant attenuates β3-AR-mediated cardiac inhibition. Vemtoberant can be used for the research of systolic heart failure .
    Vemtoberant
  • HY-P99291

    LM609; MEDI-522

    Integrin Apoptosis Akt Cancer
    Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) [3] .
    Etaracizumab
  • HY-107327
    Carazolol
    1 Publications Verification

    (±)-Carazolol; DL-Carazolol; Suacron

    Adrenergic Receptor Cardiovascular Disease
    Carazolol is a β12 adrenoceptor antagonist of high potency used in the research of hypertension. Carazolol is also a potent, selective β3-adrenoceptor agonist .
    Carazolol
  • HY-103211
    L748337
    1 Publications Verification

    Adrenergic Receptor Cardiovascular Disease Metabolic Disease Cancer
    L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The Ki values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively . L748337 couples predominantly to Gi to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC50 value of 11.6 . L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases [3].
    L748337
  • HY-P1189

    Integrin Metabolic Disease Inflammation/Immunology
    Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 [3] .
    Echistatin
  • HY-B0665

    Integrin Cardiovascular Disease
    Fibrin is an insoluble protein found in blood that is produced in response to bleeding. As the main component of blood clots, fibrin functions in blood coagulation. Fibrin binds to the integrins ICAM-1, VE-cadherin, αIIbβ3, αMβ2, αvβ3 and α5β1. Fibrin is used in research related to chronic wounds .
    Fibrin
  • HY-18668

    Integrin Cancer
    Integrin antagonist 27 (Compound 27) is a small molecule integrin αvβ3 antagonist with an affinity of 18 nM. Integrin antagonist 27 can be combined with Paclitaxel (HY-B0015) to selectively target αvβ3-positive metastatic cancer cells. Integrin antagonist 27 is used as an anticancer agent .
    Integrin antagonist 27
  • HY-P1189A

    Integrin Metabolic Disease Inflammation/Immunology
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 [3] .
    Echistatin TFA
  • HY-P0178

    Integrin Inflammation/Immunology
    LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect [3].
    LXW7
  • HY-P1187

    Integrin Cancer
    HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM) .
    HSDVHK-NH2
  • HY-105272

    R 72063

    GABA Receptor Neurological Disease
    Loreclezole, an antiepileptic compound, is a selective GABAA receptor modulator and acts as a positive allosteric modulator of β2 or β3-subunit containing receptors .
    Loreclezole
  • HY-117133

    SF0166

    Integrin Metabolic Disease
    Nesvategrast (SF0166) is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. Nesvategrast inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. Nesvategrast decreases neovascularization in the oxygen-induced retinopathy mouse model .
    Nesvategrast
  • HY-119350B

    RUC-4 dihydrochloride

    Integrin Cardiovascular Disease
    Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI) .
    Zalunfiban dihydrochloride
  • HY-19306

    Integrin Cancer
    SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with Kis of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC50s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression .
    SB-267268
  • HY-P11339

    Integrin Cancer
    c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .
    c-RGD-SH
  • HY-100672B

    Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    (2R)-SR59230A is the isomer of SR59230A (HY-100672), and can be used as an experimental control. SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively .
    (2R)-SR59230A
  • HY-118944

    Adrenergic Receptor Endocrinology
    L-748328 is a potent and selective human β3-adrenergic receptor antagonist. L-748328 has a Ki of 3.7 nM against human cloned β3-AR expressed in Chinese hamster ovary (CHO) cells. In addition, L-748328 inhibits the lipolytic response induced by the β3-AR agonist L-742791 in isolated non-human primate adipocytes .
    L-748328
  • HY-P0178A

    Integrin Inflammation/Immunology
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect [3].
    LXW7 TFA
  • HY-13713

    Adrenergic Receptor Metabolic Disease Endocrinology
    LY377604 is a human β3-adrenergic receptor agonist with an EC50 of 2.4 nM and also a β1- and β2-adrenergic receptor antagonist.
    LY377604
  • HY-W517264

    BM 51052 hydrochloride

    Adrenergic Receptor Cardiovascular Disease
    Carazolol (BM 51052) hydrochloride is a highly potent antagonist of β12 adrenoceptor. Carazolol hydrochloride is also a potent, selective β3-adrenoceptor agonist. Carazolol hydrochloride can be used in the research of hypertension .
    Carazolol hydrochloride
  • HY-162558

    Factor Xa Cardiovascular Disease
    NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-αIIbβ3 interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation .
    NCGC00351170
  • HY-15378

    ZD2079 hydrochloride

    Adrenergic Receptor Cardiovascular Disease
    Talibegron hydrochloride (ZD2079 hydrochloride) is a potent β3-adrenoceptor agonist with a pD2 of 3.72 on phenylephrine-preconstricted rat mesenteric artery. Talibegron hydrochloride has potent vasorelaxant effect .
    Talibegron hydrochloride
  • HY-N14860

    Antibiotic Bacterial Infection
    Milbemycin β3 is a macrolide antibiotic. Milbemycin β3 has insecticidal effects on agricultural harmful insects, pans, larvae, etc .
    Milbemycin β3
  • HY-175323

    Integrin PD-1/PD-L1 Cancer
    NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .
    NOTA-IMB-RGD
  • HY-119350

    RUC-4

    Integrin Cardiovascular Disease
    Zalunfiban (RUC-4) is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban can be used for the research of myocardial infarction (MI) .
    Zalunfiban
  • HY-P99560

    C4G1; YM-337

    Integrin Cardiovascular Disease
    Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
    Tadocizumab
  • HY-103524R

    (-)-Valerenic Acid (Standard)

    5-HT Receptor GABA Receptor Reference Standards Neurological Disease
    Valerenic acid (Standard) is the analytical standard of Valerenic acid. This product is intended for research and analytical applications. Valerenic acid ((-)-Valerenic Acid), a sesquiterpenoid, is an orally active positive allosteric modulator of GABAA receptors. Valerenic acid is also a partial agonist of the 5-HT5a receptor. Valerenic acid mediates anxiolytic activity via GABAA receptors containing the β3 subunit. Valerenic acid also exhibits potent antioxidant properties [3].
    Valerenic acid (Standard)
  • HY-176300

    Integrin Cancer
    RGD-DA6 is an αvβ3-targeted ligand. RGD-DA6 consists of RGDfK (an integrin αvβ3-targeted RGD peptide), DOTADG, d-Glu, Lys, AMBA, and IPBA. RGD-DA6 can be radiolabeled as an αvβ3-targeted radioligand and used for high-contrast tumor imaging and enhanced anticancer efficacy .
    RGD-DA6
  • HY-172465

    Liposome Integrin Cardiovascular Disease Cancer
    DSPE-PEG5000-cRGD is a PEG conjugate composed of DSPE and the αvβ3-targeting peptide (cRGD). The cRGD peptide specifically binds to αvβ3 on the surface of various cancer cells and neovascular cells. DSPE-PEG5000-cRGD is applicable for research on drug delivery, cancer and vascular diseases .
    DSPE-PEG5000-cRGD
  • HY-P11474

    Integrin FAK Akt ERK Metabolic Disease
    FZ1 peptide is an integrin αvβ3 agonist. FZ1 peptide binds to integrin αvβ3, effectively activates FAK, FAK-dependent AKT and ERK1/2 signaling pathways. FZ1 peptide enhances VEGFC-induced endothelial angiogenesis, accelerates diabetic skin wound healing .
    FZ1 peptide
  • HY-19277

    Adrenergic Receptor Metabolic Disease
    CP-114271 is a potent selective β3-adrenergic receptor agonist. CP-114271 possesses an in vivo efficacy in rodent models. CP-114271 can be used for obesity research .
    CP-114271
  • HY-P10783

    Peptide-Drug Conjugates (PDCs) Integrin Cancer
    BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors .
    BGC0222
  • HY-P11495

    Integrin Cardiovascular Disease
    myr-RGT is a nutmeg acylated RGT peptide. myr-RGT can be used to inhibit extracellular signaling of integrin β3. myr-RGT can be used in the research of atherosclerosis and other related conditions .
    myr-RGT
  • HY-U00391

    Adrenergic Receptor Metabolic Disease Endocrinology
    β3-AR agonist 2 is a potent and selective β3-adrenergic receptor (β3-AR) agonist with an EC50 of 8 nM.
    β3-AR agonist 2
  • HY-101514

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available β3-adrenergic receptor (β3-AR) agonist (EC50=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold) .
    β3-AR agonist 1

オンラインお問い合わせ

入力情報は安全に管理されます. 必須入力項目.

タイトル

 

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

 

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: